Buzatu I, Tataranu L, Duta C, Stoian I, Alexandru O, Dricu A
Int J Mol Sci. 2025; 26(5).
PMID: 40076810
PMC: 11899917.
DOI: 10.3390/ijms26052192.
He W, Tong L, Yuan Y, Yang X, Yang W, Pan X
Front Pharmacol. 2025; 16:1448095.
PMID: 40061962
PMC: 11885501.
DOI: 10.3389/fphar.2025.1448095.
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E
J Hematol Oncol. 2025; 18(1):6.
PMID: 39806516
PMC: 11733683.
DOI: 10.1186/s13045-024-01634-6.
Kathuria I, Singla B
World J Gastroenterol. 2024; 30(38):4249-4253.
PMID: 39493325
PMC: 11525873.
DOI: 10.3748/wjg.v30.i38.4249.
Ky T, Loan N, Thinh N, Binh M
BMC Cancer. 2024; 24(1):841.
PMID: 39009994
PMC: 11247847.
DOI: 10.1186/s12885-024-12601-2.
Three-Dimensional Hepatocyte Spheroids: Model for Assessing Chemotherapy in Hepatocellular Carcinoma.
Royo F, Garcia-Vallicrosa C, Azparren-Angulo M, Bordanaba-Florit G, Lopez-Sarrio S, Falcon-Perez J
Biomedicines. 2024; 12(6).
PMID: 38927406
PMC: 11201042.
DOI: 10.3390/biomedicines12061200.
MRI monitoring of combined therapy with transcatheter arterial delivery of NK cells and systemic administration of sorafenib for the treatment of HCC.
Zhang Z, Yu G, Eresen A, Hou Q, Yaghmai V, Zhang Z
Am J Cancer Res. 2024; 14(5):2216-2227.
PMID: 38859849
PMC: 11162671.
DOI: 10.62347/IARO1564.
Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells.
Lee P, Koseki L, Haitani T, Harada H, Kobayashi M
Cancers (Basel). 2024; 16(9).
PMID: 38730681
PMC: 11083728.
DOI: 10.3390/cancers16091729.
Preparation and characterization of Sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study.
Zaafar D, Khalil H, Elkhouly G, Sedeky A, Ahmed Y, Khalil M
Drug Deliv Transl Res. 2024; 14(11):3089-3111.
PMID: 38430357
PMC: 11445346.
DOI: 10.1007/s13346-024-01530-z.
Mechanistic Insights about Sorafenib-, Valproic Acid- and Metformin-Induced Cell Death in Hepatocellular Carcinoma.
Franco-Juarez E, Gonzalez-Villasana V, Camacho-Moll M, Rendon-Garlant L, Ramirez-Flores P, Silva-Ramirez B
Int J Mol Sci. 2024; 25(3).
PMID: 38339037
PMC: 10855535.
DOI: 10.3390/ijms25031760.
Adjuvant therapy with toceranib for hepatocellular carcinoma and cholangiocarcinoma in a Pomeranian.
Choi L, Choi J, Yoon H, Bae K, Yoon K, Kim J
Vet Med (Praha). 2024; 68(2):83-89.
PMID: 38332765
PMC: 10847815.
DOI: 10.17221/49/2022-VETMED.
Systemic Treatment in Intermediate Stage (Barcelona Clinic Liver Cancer-B) Hepatocellular Carcinoma.
Karagiannakis D
Cancers (Basel). 2024; 16(1).
PMID: 38201479
PMC: 10778557.
DOI: 10.3390/cancers16010051.
Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.
Singal A, Ozgurdal K, Fan X, Vassilev Z, Pan X, Multani J
Cancers (Basel). 2023; 15(23).
PMID: 38067235
PMC: 10705135.
DOI: 10.3390/cancers15235532.
(S)-3-(3-Fluoro-4-Methoxybenzyl)-5,6,7-Trimethoxychroman-4-One Suppresses the Proliferation of Huh7 Cells by Up-regulating P21 and Inducing G/M Phase Arrest.
Yoon H, Lee J, Kwon S, Seo S, Cho S
Cancer Genomics Proteomics. 2023; 20(6suppl):754-762.
PMID: 38035711
PMC: 10687728.
DOI: 10.21873/cgp.20422.
Current updates in HCC screening and treatment.
Hunold T, Pillai A
Clin Liver Dis (Hoboken). 2023; 22(4):122-129.
PMID: 37908865
PMC: 10615533.
DOI: 10.1097/CLD.0000000000000083.
Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials.
Tan D, Tang A, Lim W, Ng C, Nah B, Fu C
Liver Cancer. 2023; 12(5):445-456.
PMID: 37901764
PMC: 10601853.
DOI: 10.1159/000529824.
From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
Dewdney B, Jenkins M, Best S, Freytag S, Prasad K, Holst J
Signal Transduct Target Ther. 2023; 8(1):400.
PMID: 37857607
PMC: 10587102.
DOI: 10.1038/s41392-023-01637-8.
Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials.
Konaklieva M, Plotkin B
Antibiotics (Basel). 2023; 12(9).
PMID: 37760715
PMC: 10525673.
DOI: 10.3390/antibiotics12091418.
Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma.
Basu A, Namporn T, Ruenraroengsak P
Pharmaceutics. 2023; 15(6).
PMID: 37376061
PMC: 10302838.
DOI: 10.3390/pharmaceutics15061611.
Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression.
Zheng C, Zhang B, Li Y, Liu K, Wei W, Liang S
Adv Sci (Weinh). 2023; 10(22):e2206798.
PMID: 37330650
PMC: 10401117.
DOI: 10.1002/advs.202206798.
